Valuation: Adimmune Corporation

Market Cap 7.44B 232M 203M 188M 173M 328M 22.18B 335M 2.25B 876M 10.85B 870M 851M 37.67B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 8.05B 251M 220M 203M 188M 356M 24B 363M 2.44B 948M 11.75B 941M 921M 40.77B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.23%
Yield 2024 *
-
Yield 2025 -
1 day-0.28%
1 week+0.86%
Current month+0.28%
3 months-3.02%
6 months-9.95%
Current year-6.86%
1 week 17.4
Extreme 17.4
18.2
1 month 16.8
Extreme 16.8
18.45
Current year 16.8
Extreme 16.8
21.5
1 year 16.35
Extreme 16.35
22.5
3 years 15.9
Extreme 15.9
38
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.28%+0.86%+10.31%-51.44% 232M
-1.97%+6.11%+21.02%-4.27% 67.44B
0.00%-6.01%+46.04%+217.06% 53.98B
-4.15%+36.30%+36.30%+36.30% 41.77B
+0.99%+6.61%-48.49%-52.47% 41.15B
-2.60%-4.47%+49.01%-27.16% 29.58B
-7.48%+1.79%+126.80%-37.92% 29.28B
-0.67%+3.03%+73.28%+88.92% 23.43B
+0.17%+1.17%+4.98%+190.25% 19.11B
+0.25%-1.29%+66.93%+131.83% 16.82B
Average -1.58%+1.68%+38.62%+49.11% 32.28B
Weighted average by Cap. -1.77%+1.53%+35.71%+52.03%

Financials

2024 2025
Net sales 1.56B 48.47M 42.51M 39.25M 36.27M 68.75M 4.64B 70.12M 472M 183M 2.27B 182M 178M 7.88B 1.4B 43.63M 38.27M 35.33M 32.65M 61.88M 4.18B 63.12M 425M 165M 2.04B 164M 160M 7.1B
Net income -243M -7.56M -6.63M -6.12M -5.65M -10.72M -724M -10.93M -73.57M -28.58M -354M -28.38M -27.76M -1.23B -240M -7.47M -6.55M -6.05M -5.59M -10.59M -715M -10.8M -72.7M -28.25M -350M -28.04M -27.43M -1.21B
Net Debt 140M 4.34M 3.81M 3.52M 3.25M 6.16M 416M 6.29M 42.29M 16.43M 204M 16.32M 15.96M 707M 612M 19.06M 16.72M 15.44M 14.26M 27.03M 1.83B 27.58M 186M 72.1M 893M 71.58M 70.01M 3.1B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
08/07/26 NT$17.65 -0.28% 671,787
07/07/26 NT$17.70 -1.39% 908,800
06/07/26 NT$17.95 +0.84% 1,362,851
03/07/26 NT$17.80 +2.30% 1,973,014
02/07/26 NT$17.40 -0.57% 798,398
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock